Latest revenue
$3.37B
as of 2026-03-28
Latest net income
$107.0M
as of 2026-03-28
Net margin
3.2%
as of 2026-03-28
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Wholesale-Medical, Dental & Hospital Equipment & Supplies (3 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think HSIC is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $8.82B
- Enterprise value
- $12.09B
- P/E (trailing)
- 22.2×
- Forward P/E
- —
- P/B
- 2.70×
- Dividend yield
- 0.0%
- 52-wk high
- $89.29
- 52-wk low
- $61.95
- Beta
- —
- Shares out
- 113.9M
5-year trend
What this company does
Business General Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. We believe we are the world’s largest provider of health care products and services primarily to office- based dental and medical practitioners, as well as alternate sites of care. Our philosophy is grounded in our commitment to serve as trusted advisors and help customers operate a more efficient and successful business so the practitioner can provide better clinical care. With 94 years of experience distributing health care products, we have built a vast base of small, mid-sized and large customers in the dental and medical markets, serving more than one…
AI summary unavailable — showing raw filing excerpt
Generated from HSIC's filing dated 2026-02-24
Key risks
Our business operations could be affected by factors that are not presently known to us or that we currently consider not to be material to our operations, so you should not consider the risks disclosed in this section to necessarily represent a complete statement of all risks and uncertainties. The Company believes that the following risks could have a material adverse impact on our business, reputation, operating results, financial condition and/or the trading price of our common stock. The order in which these factors appear does not necessarily reflect their relative importance or priority. COMPANY RISKS We are dependent upon third parties for the manufacture/supply of a significant…
AI summary unavailable — showing raw filing excerpt
Generated from HSIC's filing dated 2026-02-24
Profitability
Gross margin
31.1%
1.7%Operating margin
5.0%
1.1%Net margin
3.0%
1.9%Return on equity
12.3%
6.7%Return on assets
3.5%
7.0%Leverage
Debt / equity
2.46×
22.1%Long-term debt / equity
0.71×
32.0%Debt / assets
71.1%
6.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-28 | $3.37B | +6.3% | $107.0M | -2.7% | 3.2% |
Q4 2025 2025-12-27 | $3.44B | +7.7% | $101.0M | +7.4% | 2.9% |
Q3 2025 2025-09-27 | $3.34B | +5.2% | $101.0M | +2.0% | 3.0% |
Q2 2025 2025-06-28 | $3.24B | +3.3% | $86.0M | -17.3% | 2.7% |
Q1 2025 2025-03-29 | $3.17B | -0.1% | $110.0M | +18.3% | 3.5% |
Q4 2024 2024-12-28 | $3.19B | — | $94.0M | — | 2.9% |
Q3 2024 2024-09-28 | $3.17B | +0.4% | $99.0M | -27.7% | 3.1% |
Q2 2024 2024-06-29 | $3.14B | +1.2% | $104.0M | -25.7% | 3.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Wholesale-Medical, Dental & Hospital Equipment & Supplies · SIC 5047
Your notes
Keep private notes on HSIC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$1.4M
Insider selling
$8.6M
Net activity
−$7.2M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns HSIC
Institutional value
$3.99B
Total shares held
56.9M
Distinct holders
380
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7.0M | $517.6M | — | New |
| 2 | Artisan Partners Limited Partnership | 6.6M | $484.4M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 6.4M | $473.4M | — | New |
| 4 | Invesco Ltd. | 4.9M | $360.1M | — | New |
| 5 | JPMORGAN CHASE & CO | 4.6M | $331.7M | — | New |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.2M | $309.2M | — | New |
| 7 | DIMENSIONAL FUND ADVISORS LP | 2.9M | $211.7M | — | New |
| 8 | BANK OF MONTREAL /CAN/ | 2.0M | $150.6M | — | New |
| 9 | LYRICAL ASSET MANAGEMENT LP | 1.5M | $113.8M | — | New |
| 10 | Swedbank AB | 1.3M | $96.6M | — | New |
| 11 | UBS Group AG | 1.1M | $77.8M | — | New |
| 12 | PZENA INVESTMENT MANAGEMENT LLC | 887.6K | $65.4M | — | New |
| 13 | VANGUARD FIDUCIARY TRUST CO | 561.2K | $41.4M | — | New |
| 14 | Bank of New York Mellon Corp | 545.6K | $40.2M | — | New |
| 15 | STALEY CAPITAL ADVISERS INC | 450.7K | $33.2M | — | New |
| 16 | DEUTSCHE BANK AG\ | 415.3K | $30.6M | — | New |
| 17 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 371.0K | $27.3M | — | New |
| 18 | Leith Wheeler Investment Counsel Ltd. | 355.3K | $26.2M | — | New |
| 19 | PRIVATE MANAGEMENT GROUP INC | 331.2K | $24.4M | — | New |
| 20 | Nuveen, LLC | 282.3K | $20.8M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once HSIC's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.